Pharmaceutical Preparations · DE · CIK 1776111
MBX Biosciences develops precision peptide therapies for endocrine and metabolic disorders using its PEP platform
Comparable business profile · signals at a glance
In the 90 days to Mar 13, 2026: 1 insider bought $526K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 13, 2026 | Hawryluk P. KentPresident & CEO | Buy | 18,500 | $28.41 | $526K |
| Oct 20, 2025 | Hawryluk P. KentPresident & CEO | Buy | 20,000 | $13.64 | $273K |
| Oct 17, 2025 | Hoerter Steven L.Director | Buy | 20,000 | $13.25 | $265K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.